NicOx continues phase 3 study of naproxcinod in osteoarthritis

By Lisa Kerner

Charlotte, N.C., Sept. 6 - NicOx SA announced plans for its phase 3 clinical program for the anti-inflammatory naproxcinod (HCT 3012) for treating osteoarthritis.

The plan, including three phase 3 efficacy trials, is designed to gain regulatory approval for naproxcinod in the United States and Europe.

One U.S. trial in knee osteoarthritis is ongoing, while a similar trial in knee osteoarthritis is expected to start in the first quarter of 2007.

Both knee osteoarthritis trials will include a year or more of safety data, with data expected in the fourth-quarter 2008.

A third trial in hip osteoarthritis is planned for the third quarter of 2007.

NicOx is a biopharmaceutical company located in Sophia-Antipolis, France.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.